Now the FDA Comes Clean...FINALLY!!!

[Elkchester Road]

Originally Posted by Jeff P

The Mafia used to offer something similar to small business owners.

They called it 'Protection' and heaven help you if you said "No."


-jp

.

The similarities are eerie, Jeff.

[Jeff P]

New Preprint Study funded by The NIH using data from Moderna's clinical vaccine trial finds the vaccinated have significantly lower likelihood of developing natural immunity after Covid infection than the unvaccinated.

AND... according to the study, the likely explanation is "vaccine-induced reduction in seroconversion."

medRxIv | April 19, 2022
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial:
https://www.medrxiv.org/content/10.1...2271936v1.full

Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michaël Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden

doi: https://doi.org/10.1101/2022.04.18.22271936


Abstract

Importance The performance of immunoassays for determining past SARS-CoV-2 infection, which were developed in unvaccinated individuals, has not been assessed in vaccinated individuals.

Objective To evaluate anti-nucleocapsid antibody (anti-N Ab) seropositivity in mRNA-1273 vaccine efficacy trial participants after SARS-CoV-2 infection during the trial’s blinded phase.

Design Nested analysis in a Phase 3 randomized, placebo-controlled vaccine efficacy trial. Nasopharyngeal swabs for SARS-CoV-2 PCR testing were taken from all participants on Day 1 and Day 29 (vaccination days), and during symptom-prompted illness visits. Serum samples from Days 1, 29, 57, and the Participant Decision Visit (PDV, when participants were informed of treatment assignment, median day 149) were tested for anti-N Abs.

Setting Multicenter, randomized, double-blind, placebo-controlled trial at 99 sites in the US.

Results We analyzed data from 1,789 participants (1,298 placebo recipients and 491 vaccine recipients) with SARS-CoV-2 infection during the blinded phase (through March 2021). Among participants with PCR-confirmed Covid-19 illness, seroconversion to anti-N Abs at a median follow up of 53 days post diagnosis occurred in 21/52 (40%) of the mRNA-1273 vaccine recipients vs. 605/648 (93%) of the placebo recipients (p < 0.001). Higher SARS-CoV-2 viral copies at diagnosis was associated with a higher likelihood of anti-N Ab seropositivity (odds ratio 1.90 per 1-log increase; 95% confidence interval 1.59, 2.28).

Conclusions and Relevance As a marker of recent infection, anti-N Abs may have lower sensitivity in mRNA-1273-vaccinated persons who become infected. Vaccination status should be considered when interpreting seroprevalence and seropositivity data based solely on anti-N Ab testing

Trial Registration ClinicalTrials.gov NCT04470427

Question Does prior mRNA-1273 vaccination influence anti-nucleocapsid antibody seroconversion and/or seroreversion after SARS-CoV-2 infection?

Findings Among participants in the mRNA-1273 vaccine efficacy trial with PCR-confirmed Covid-19, anti-nucleocapsid antibody seroconversion at the time of study unblinding (median 53 days post diagnosis and 149 days post enrollment) occurred in 40% of the mRNA-1273 vaccine recipients vs. 93% of the placebo recipients, a significant difference.

Discussion

These data show that, among the participants with PCR-confirmed Covid-19 disease, anti-N Ab seropositivity at a median of 53 days post diagnosis occurred in 40% of the mRNA-1273 vaccine recipients vs. 93% of the placebo recipients. While an increase in seroreversion cannot be ruled out, given the short time frame the more likely explanation is a vaccine-induced reduction in seroconversion.

Imo, this is huge.

Keep in mind the study still has to undergo peer review.

However, the data is from Moderna's clinical vaccine trial and the study was funded by The NIH.

These findings suggest the mRNA Vaccines make it harder for the vaccinated to develop natural immunity after Covid infection than the vaccinated.

This would help explain Covid reinfections among the vaccinated.



-jp

.

[JustRalph]

Originally Posted by Jeff P

New Preprint Study funded by The NIH using data from Moderna's clinical vaccine trial finds the vaccinated have significantly lower likelihood of developing natural immunity after Covid infection than the unvaccinated.

AND... according to the study, the likely explanation is "vaccine-induced reduction in seroconversion."

medRxIv | April 19, 2022
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial:
https://www.medrxiv.org/content/10.1...2271936v1.full






Imo, this is huge.

Keep in mind the study still has to undergo peer review.

However, the data is from Moderna's clinical vaccine trial and the study was funded by The NIH.

These findings suggest the mRNA Vaccines make it harder for the vaccinated to develop natural immunity after Covid infection than the vaccinated.

This would help explain Covid reinfections among the vaccinated.



-jp

.

Christ! This is huge

[boxcar]

Originally Posted by JustRalph

Christ! This is huge

But many doctors and medical scientist have deduced this quite a while ago. To put into layman's vernacular: The jabs screw with your immune system. Do you remember way back when...when the small island of Gibraltar had a breakout of covid even though at least 98% of the population had been jabbed!? And this was well over a year ago.

Quite a little racket Big Pharma has. A genuine Cash Cow that can be milked indefinitely. You jab people with your toxic crap that will compromise your immune system forever, which guarantees that you'll need to be jabbed for the rest of your life. And each shot has to be bought and paid for by someone! Big Pharma isn't in the charity business.